Neurogene Inc. NGNE 深 沪
等待开盘 03-26 09:30:00 美东时间
22.05
+1.150
+5.50%
华盛通- 最 高23.35
- 今 开21.24
- 成交量 11.38万股
- 最 低 20.81
- 昨 收 20.90
- 总市值 3.42亿
- 52周最高 37.2659
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 6.875
- 委 比 0.00%
- 总股本 1548.98万
- 历史最高 362.60
- 量 比 0.66
- 振 幅 12.15%
- 历史最低 6.875
- 每 手 1
- 风险率 4.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neurogene shares are trading higher. The company reported Q4 financial results.
Neurogene shares are trading higher. The company reported Q4 financial results.
今天 00:09
Neurogene Q4 EPS $(1.13), Inline
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consensus estimate. This is a 13 percent decrease over losses of $(1.00) per share from the same period last year.
03-24 19:39
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday
Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gainers include AAOI, NGNE, ARLO, PRAA, BYND, BWIN, PSKY, & DELL.
02-28 01:52
Neurogene shares are trading higher after the company announced that the FDA granted Breakthrough Therapy designation to NGN-401.
Neurogene shares are trading higher after the company announced that the FDA gr...
02-27 05:56
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
LifeSci Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $50
LifeSci Capital analyst Patrick Dolezal initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $50.
01-26 21:45
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $70 price target.
01-13 20:20
Neurogene Grants Stock Options to New Employees Under 2025 Inducement Plan
Neurogene Inc. has approved the grant of non-qualified stock options to purchase a total of 4,860 shares of the company's common stock for two new employees. These options have an exercise price equal...
2025-12-05 05:01
